AVITA Medical (RCEL) announced the US commercial launch of its wound care product Cohealyx.
The product was co-developed with Regenity Biosciences, AVITA said Thursday in a statement.
Cohealyx was designed to support cell movement, improve blood vessel formation and create a foundation for wound healing, AVITA said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.